869366-09-6

Basic information

• Product Name: (E)-8-chloro-1-(2,6-difluorophenyl)-3,4-dihydrobenzo[c]azepin-5-one
• Synonyms: (E)-8-chloro-1-(2,6-difluorophenyl)-3,4-dihydrobenzo[c]azepin-5-one;8-chloro-1-(2,6-difluorophenyl)-3H-benzo[c]azepin-5(4H)-one;8-Chloro-1-(2,6-difluorophenyl)-3,4-dihydro-benzo[c]azepin-5-one;8-chloro-1-(2,6-difluorophenyl)-3,4-dihydro-2-benzazepin-5-one
• CAS NO: 869366-09-6
• Molecular Formula: C₁₆H₁₀ClF₂NO
• Molecular Weight: 305.7065064
• Mol File: 869366-09-6.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 419.7±45.0 °C(Predicted)
• Appearance: /
• Density: 1.37±0.1 g/cm3(Predicted)
• PKA: 1.87±0.20(Predicted)
• CAS DataBase Reference: (E)-8-chloro-1-(2,6-difluorophenyl)-3,4-dihydrobenzo[c]azepin-5-one(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-8-chloro-1-(2,6-difluorophenyl)-3,4-dihydrobenzo[c]azepin-5-one(869366-09-6)
• EPA Substance Registry System: (E)-8-chloro-1-(2,6-difluorophenyl)-3,4-dihydrobenzo[c]azepin-5-one(869366-09-6)

Safety Data

• Hazardous Substances Data: 869366-09-6(Hazardous Substances Data)

Usage

Description

(E)-8-chloro-1-(2,6-difluorophenyl)-3,4-dihydrobenzo[c]azepin-5-one is a chemical compound belonging to the benzazepines class, with a molecular formula of C16H10ClF2NO. It is characterized by its potent and selective antagonism of dopamine D2-like receptors in the brain, which can potentially influence the treatment of neurological and psychiatric disorders.

Uses

Used in Pharmaceutical Industry:
(E)-8-chloro-1-(2,6-difluorophenyl)-3,4-dihydrobenzo[c]azepin-5-one is used as a therapeutic agent for targeting neurological and psychiatric disorders. Its ability to block dopamine receptors makes it a candidate for treating conditions such as schizophrenia, bipolar disorder, and drug addiction. (E)-8-chloro-1-(2,6-difluorophenyl)-3,4-dihydrobenzo[c]azepin-5-one has demonstrated antipsychotic and antidepressant effects in preclinical studies, indicating its potential in managing the symptoms of these disorders.
However, it is important to note that further research and clinical trials are necessary to establish the safety and efficacy of (E)-8-chloro-1-(2,6-difluorophenyl)-3,4-dihydrobenzo[c]azepin-5-one before it can be incorporated into medical treatments.

Upstream product

• 869366-03-0 tert-butyl (3-(4-chloro-2-(2,6-difluorobenzoyl)phenyl)prop-2-yn-1-yl)carbamate 
• 18437-66-6 N-(t-butoxycarbonyl)-4-chloroaniline 
• 28910-83-0 (2-amino-5-chlorophenyl)-(2,6-difluorophenyl)methanone 
• 869365-97-9 (5-chloro-2-iodophenyl)(2,6-difluorophenyl)methanone 
• 869365-92-4 tert-butyl (4-chloro-2-(2,6-difluorobenzoyl)phenyl)carbamate 

Downstream Products

• 869363-13-3 4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzoic acid 
• 1393381-45-7 tert-butyl (1-(2-(4-((9-chloro-7-(2,6-difluorophenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl)amino)benzamido)ethyl)piperidin-4-yl)carbamate 
• 1393381-46-8 N-(2-(4-aminopiperidin-1-yl)ethyl)-4-((9-chloro-7-(2,6-difluorophenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl)amino)benzamide 
• 869366-10-9 8-chloro-4-[(dimethylamino)methylene]-1-(2,6-difluorophenyl)-3,4-dihydro-5H-2-benzazepin-5-one 

Relevant articles and documents

MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A Inhibitors

The Aurora kinases are essential for cell mitosis, and the dysregulation of Aurora A and B have been linked to the etiology of human cancers. Investigational agents MLN8054 (8) and alisertib (MLN8237, 10) have been identified as high affinity, selective,

Compounds and methods for inhibiting mitotic progression

This invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treat